The estimated Net Worth of Frank L Jr Jaksch is at least $1.4 Millón dollars as of 12 June 2023. Mr. Jaksch owns over 7,000 units of Chromadex Corp stock worth over $768,045 and over the last 8 years he sold CDXC stock worth over $0. In addition, he makes $636,778 as Executive Chairman of the Board at Chromadex Corp.
Frank has made over 10 trades of the Chromadex Corp stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 7,000 units of CDXC stock worth $11,830 on 12 June 2023.
The largest trade he's ever made was exercising 58,400 units of Chromadex Corp stock on 21 December 2017 worth over $262,800. On average, Frank trades about 11,507 units every 138 days since 2016. As of 12 June 2023 he still owns at least 231,339 units of Chromadex Corp stock.
You can see the complete history of Mr. Jaksch stock trades at the bottom of the page.
Frank L. Jaksch Jr. serves as Executive Chairman of the Board of the Company. He is a Co-Founder of the Company and has served as a member of the Board since February 2000. Mr. Jaksch served as Chairman of the Board from May 2010 to October 2011 and was its Co-Chairman from February 2000 to May 2010. In June 2018, Mr. Jaksch transitioned from Chief Executive Officer to Executive Chairman of the Board. Mr. Jaksch oversees research, strategy and operations for the Company with a focus on scientific and novel products for pharmaceutical and nutraceutical markets. From 1993 to 1999, Mr. Jaksch served as International Subsidiaries Manager of Phenomenex, a life science supply company where he managed the international subsidiary and international business development divisions. Mr. Jaksch earned a B.S. in Chemistry and Biology from Valparaiso University. The Nominating and Corporate Governance Committee believes that Mr. Jaksch’s years of experience working in chemistry-related industries, his extensive sales and marketing background, and his knowledge of international business bring an understanding of the industries in which the Company operates as well as scientific expertise to the Board.American Botanical Council and the NSF Joint Committee for Dietary Supplements.
As the Executive Chairman of the Board of Chromadex Corp, the total compensation of Frank Jaksch at Chromadex Corp is $636,778. There are 2 executives at Chromadex Corp getting paid more, with Robert Fried having the highest compensation of $1,711,890.
Frank Jaksch is 51, he's been the Executive Chairman of the Board of Chromadex Corp since 2018. There are 12 older and 3 younger executives at Chromadex Corp. The oldest executive at Chromadex Corp is Stephen Block, 75, who is the Independent Director.
Frank's mailing address filed with the SEC is 10900 WILSHIRE BLVD. SUITE 600, , LOS ANGELES, CA, 90024.
Over the last 16 years, insiders at Chromadex Corp have traded over $0 worth of Chromadex Corp stock and bought 25,157,946 units worth $26,482,051 . The most active insiders traders include Ka Shing Prime Tech Global ..., Hoi Shuen Solina Holly Pion... y Steven D Rubin. On average, Chromadex Corp executives and independent directors trade stock every 120 days with the average trade being worth of $2,496,872. The most recent stock trade was executed by Kristin Patrick on 23 August 2024, trading 23,000 units of CDXC stock currently worth $38,410.
chromadex corp. is an integrated, global nutraceutical company devoted to improving the way people age. chromadex scientists partner with leading universities and research institutions worldwide to uncover the full potential of nad and identify and develop novel, science-based ingredients including pteropure® pterostilbene; purenergy®, a caffeine-pteropure® co-crystal; anthorigin™, anthocyanins and niagen® nicotinamide riboside - sold directly to consumers as the supplement, tru niagen®. tru niagen® is helping the world age better®. for more, visit www.chromadex.com like us on facebook here: https://www.facebook.com/chromadex or follow us on twitter @chromadex chromadex® is publicly-traded company (nasdaq:cdxc).
Chromadex Corp executives and other stock owners filed with the SEC include: